DUBLIN, March 28, 2024 /PRNewswire/ -- The 'Molecular Diagnostics for Cancer: Markets Forecasts by Cancer Type, Product, and Place with Executive & Consultant Guides and Customization. 2023 to 2027' report has been added to  ResearchAndMarkets.com's offering.

都柏林，2024年3月28日/PRNewswire/--The'Molecular Diagnostics for Cancer:Markets for Cancer Type，Product and Place Forecast with Executive&Consultant Guide and Customization。《2023年至2027年报告》已添加到ResearchAndMarkets.com的产品中。

Exciting technical developments especially in companion diagnostics, hold the promise of a dynamic, growing and evolving world market where single laboratories serve a global patient base.

令人兴奋的技术发展，特别是在伴随诊断方面，有望成为一个动态的，不断增长和不断发展的世界市场，其中单个实验室服务于全球患者群体。

The report provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current United States Medicare Fee Payment Schedules to help understand test pricing in detail. Make facilities planning decisions. Forecast demand for new testing regimes or technologies.

该报告提供了分析师和规划师可以使用的数据。数百页的信息，包括当前美国医疗保险费用支付时间表的完整列表，有助于详细了解测试定价。制定设施规划决策。预测对新测试制度或技术的需求。

Make research investment decisions..

做出研究投资决策。。

Assistance in providing specific growth and market size estimates for new technology tests is normally provided without additional charges. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities' growth. Again, assistance in using the information is normally provided without additional charges..

为新技术测试提供特定增长和市场规模估计方面的援助通常不收取额外费用。现有的实验室和医院可以直接使用这些信息来预测和规划临床设施的增长。同样，使用信息的帮助通常不需要额外费用。。

After a pandemic interruption the market for Cancer Molecular Diagnostics is back on the growth path. And growth is accelerating in every segment. We include a special segment Cancer Companion Diagnostics, a new segment of the market that is reshaping the industry. Over 120 companies are profiled. A range of dynamic trends are pushing market growth and company valuations..

在大流行中断后，癌症分子诊断市场重新走上增长之路。各个领域的增长都在加速。我们包括一个特殊的细分市场癌症伴随诊断，这是一个正在重塑行业的新细分市场。介绍了120多家公司。一系列动态趋势正在推动市场增长和公司估值。。

Key Market Trends

主要市场趋势

Personalized medicine

个性化医疗

Pharmacogenomics

药物基因组学

Liquid biopsy

液体活检

Minimal residual disease testing

最小残留疾病检测

Emergence of new economies with large markets

具有大市场的新经济体的出现

Physician diagnostics being displaced by new intelligent diagnostic tests

医生诊断被新的智能诊断测试所取代

Key Topics Covered:

涵盖的关键主题：

1 Market Guides1.1 Cancer MDx - Strategic Situation Analysis1.2 Guide for Executives, Marketing, and Business Development Staff1.3 Guide for Management Consultants and Investment Advisors

1市场指南1.1癌症MDx-战略形势分析1.2高管、营销和业务发展人员指南1.3管理顾问和投资顾问指南

2 Introduction and Market Definition2.1 What are Molecular Diagnostics?2.2 The Diagnostics Revolution2.3 Market Definition2.3.1 Revenue Market Size2.4 Methodology2.4.1 Methodology2.4.2 Sources2.4.3 Authors2.5 Perspective: Healthcare and the IVD Industry2.5.1 Global Healthcare Spending2.5.2 Spending on Diagnostics2.5.3 Important Role of Insurance for Diagnostics.

2简介和市场定义2.1什么是分子诊断？2.2诊断革命2.3市场定义2.3.1收入市场规模2.4方法2.4.1方法2.4.2来源2.4.3作者2.5观点：医疗保健和IVD行业2.5.1全球医疗保健支出2.5.2诊断支出2.5.3诊断保险的重要作用。

3 Market Overview3.1 Market Segments3.1.1 Traditional Market Segmentation3.1.2 Laboratory Focus and Segmentation3.2 Industry Structure3.2.1 Hospital Testing Share3.2.2 Economies of Scale3.2.3 Physician Office Labs3.2.4 Physicians and POCT

3市场概述3.1市场细分3.1.1传统市场细分3.1.2实验室重点和细分3.2行业结构3.2.1医院检测份额3.2.2规模经济3.2.3医生办公室实验室3.2.4医生和POCT

4 Market Trends4.1 Factors Driving Growth4.1.1 New Diagnostics Create New Markets4.1.2 New Roles for Diagnostics4.1.3 The Aging Effect4.1.4 Expanding the Pharmaceutical Toolbox4.1.5 Regulatory Retreat4.2 Factors Limiting Growth4.2.1 Falling Prices4.2.2 Lower Costs4.2.3 Wellness has a Downside4.3 Instrumentation, Automation and Diagnostic Trends4.3.1 Traditional Automation and Centralization4.3.2 The New Automation, Decentralization and Point Of Care4.3.3 Instruments Key to Market Share4.3.4 Bioinformatics Plays a Role4.3.5 PCR Takes Command4.3.6 Next Generation Sequencing Fuels a Revolution4.3.7 NGS Impact on Pricing4.3.8 Whole Genome Sequencing, A Brave New World4.3.9 Companion Diagnostics Blurs Diagnosis and Treatment4.3.10 Shifting Role of Diagnostics4.3.11 Multiplexing and Foundation One4.3.12 Pharmacogenomics Technology4.3.13 Gene Editing and Gene Therapy.

4市场趋势4.1推动增长的因素4.1.1新诊断创造新市场4.1.2诊断的新角色4.1.3衰老效应4.1.4扩大制药工具箱4.1.5监管退缩4.2限制增长的因素4.2.1价格下跌4.2.2成本降低4.2.3健康有下降趋势4.3仪器，自动化和诊断趋势4.3.1传统的自动化和集中化4.3.2新的自动化，分散化和护理点4.3.3仪器对市场份额至关重要4.3.4生物信息学发挥作用4.3.5 PCR需要命令4.3.6下一代测序推动了一场革命4.3.7 NGS对Pricing4.3.8全基因组测序，一个勇敢的新世界4.3.9伴随诊断模糊了诊断和治疗4.3.10诊断的角色转变4.3.11多路复用和基础4.3.12药物基因组学技术4.3.13基因编辑和基因治疗。

5 Molecular Diagnostics Recent Developments 5.1 Recent Developments - Importance and How to Use This Section 5.1.1 Importance of These Developments 5.1.2 How to Use This Section 5.2 Grail Cancer Test Faces New Clinical Questions 5.3 Freenome Acquires Cancer Dx Firm Oncimmune 5.4 Quest Diagnostics to Acquire Liquid Biopsy Firm Haystack Oncology 5.5 Ultima Genomics, Genome Insight Partner on WGS for Cancer Patients 5.6 Digital Pathology Meets Cancer Sequencing 5.7 Exact Sciences Preps Expanded Oncology Portfolio 5.8 Qiagen Details Oncology Plans for Digital PCR Platform5.9 Sema4 Exiting Reproductive Health Screening5.10 Thermo Fisher Introduces Cancer Profiling Assay 5.11 Genomic Test IDs Cysts Likely to Progress to Cancer 5.12 Naveris to Commercialize Virus-Related Cancer Tests5.13 Larger Liquid Biopsy Panels Loom 5.14 Halo Diagnostics to Offer Genomic Profiling Tests5.15 BillionToOne Raises $125M 5.16 Local Cancer Genomic Profiling Options Grow 5.17 German MDx Firm Mainz Biomed Raises $10M in IPO 5.18 Guardant Health Q3 Revenues Up 27 Percent5.19 BforCure Raises $2.3M to Adapt Rapid PCR Platform for Cancer Detection 5.20 Nucleix to Invest in Early-Stage Lung Cancer Dx 5.21 Labcorp, GeneCentric Partnering on Development of RNA-Based Cancer Diagnostics5.22 Grail Gets Approval for Galleri Multicancer Test5.23 Finnish Firms to Form Point-of-Care Testing Firm 5.24 Datar Cancer Genetics Expands to Dx and Screening 5.25 HTG Molecular Diagnostics: HTG Transcriptome Panel 5.26 PacBio's Omniome Acquisition Shortens Path to Clinical 5.27 Invitae to Acquire Genosity for $200M5.28 Bio-Techne Obtains CE Mark for Exosomal Liquid Biopsy Prostate Test5.29 Agilent Technologies to Acquire Liquid Biopsy Firm Resolution Bioscience5.30 Natera Revenues Grow 35 Percent 5.31 AnchorDx Closes $40.

5分子诊断学最新发展5.1最新发展-重要性和如何使用本节5.1.1这些发展的重要性5.1.2如何使用本节5.2 Grail癌症测试面临新的临床问题5.3 Freenome收购Cancer Dx Firm Oncimmune 5.4 Quest Diagnostics收购液体活检公司Haystack Oncology 5.5 Ultima Genomics，Genome Insight Partner on WGS for Cancer Patients 5.6 Digital Pathology Meeting Cancer Sequencing 5.7 Exact Sciences Preps Extended Oncology Portfolio 5.8 Qiagen详细介绍数字PCR平台的肿瘤学计划5.9 Sema4退出生殖健康筛查5.10 Thermo Fisher引入癌症分析检测5.11基因组检测ID囊肿可能发展为癌症5.12 Naveris将病毒相关癌症检测商业化5.13更大的液体活检面板隐现5.14 Halo Diagnostics提供基因组分析检测5.15亿Toone筹集1.25亿美元5.16当地癌症基因组分析选项增长5.17德国MDx公司Mainz Biomed在IPO中筹集1000万美元5.18 Guardantipo 3 Health第三季度收入增长27%5.19 BforCure筹集230万美元用于癌症检测的快速PCR平台5.20 Nucleix投资于早期肺癌Dx 5.21 Labcorp，基因中心合作开发基于RNA的癌症诊断5.22 Grail获得Galleri Multicancer Test的批准5.23芬兰公司成立即时检测公司5.24 Datar Cancer Genetics扩展到Dx和筛查5.25 HTG Molecular Diagnostics:HTG Transcriptome Panel 5.26 PacBio的Omniome收购缩短了通往临床的道路5.27 Invitae以200美元收购Genosity 5.28 Bio-Techne获得外泌体液体活检前列腺测试的CE标志5.29安捷伦科技收购液体活检公司Resolution Bioscience5.30 Natera收入增长35%5.31 AnchorDx以40美元收盘。

6 Profiles of Key MDx Companies6.1 10x Genomics, Inc.6.2 Abbott Laboratories6.3 AccuraGen Inc.6.4 Adaptive Biotechnologies6.5 Aethlon Medical6.6 Agilent/Dako6.7 Anchor Dx6.8 ANGLE plc6.9 ARUP Laboratories6.10 AVIVA Systems Biology6.11 Baylor Miraca Genetics Laboratories6.12 Beckman Coulter Diagnostics6.13 Becton, Dickinson and Company6.14 BGI Genomics Co.

6主要MDx公司简介6.1 10x Genomics，Inc.6.2雅培实验室6.3 AccuraGen Inc.6.4自适应生物技术6.5 Aethlon Medical6.6安捷伦/达科6.7 Anchor Dx6.8 ANGLE plc6.9 ARUP实验室6.10 AVIVA Systems Biology6.11 Baylor Miraca Genetics Laboratories 6.12 Beckman Coulter Diagnostics 6.13 Becton，Dickinson and Company6.14 BGI Genomics Co。

Ltd6.15 BillionToOne6.16 Bioarray Genetics6.17 Biocartis6.18 Biocept, Inc.6.19 Biodesix Inc.6.20 BioFluidica6.21 BioGenex6.22 BioIVT6.23 Biolidics Ltd6.24 bioMerieux Diagnostics6.25 Bioneer Corporation6.26 Bio-Rad Laboratories, Inc6.27 Bio-Reference Laboratories6.28 Bio-Techne6.29 Bioview6.30 Bolidics6.31 Boreal Genomics6.32 Bristol-Myers Squibb6.33 Burning Rock6.34 Cardiff Oncology6.35 Caris Molecular Diagnostics6.36 Castle Biosciences, Inc.6.37 Celemics6.38 CellCarta6.39 CellMax Life6.40 Cepheid (Danaher)6.41 Charles River Laboratories6.42 Circulogene6.43 Cizzle Biotech6.44 Clinical Genomics6.45 Cytolumina Technologies Corp.6.46 Datar Cancer Genetics Limited6.47 Diagnologix LLC6.48 Diasorin S.p.A.6.49 Dxcover6.50 Enzo Biochem6.51 Epic Sciences6.52 Epigenomics AG6.53 Eurofins Scientific6.54 Exact Sciences6.55 Fabric Genomics6.56 Fluxion Biosciences6.57 Freenome6.58 FUJIFILM Wako Diagnostics6.59 Fulgent Genetics6.60 Fyr Diagnostics6.61 GeneFirst Ltd.6.62 Genetron Holdings6.63 GenomOncology6.64 GILUPI Nanomedizin6.65 Guardant Health6.66 HansaBiomed6.67 HeiScreen6.68 Helomics6.69 HTG Molecular Diagnostics6.70 iCellate6.71 ICON PLC6.72 Illumina6.73 Incell Dx6.74 Inivata6.75 INOVIQ6.76 Integrated Diagnostics6.77 Invitae Corporation6.78 Invivogen6.79 Invivoscribe6.80 Janssen Diagnostics6.81 Lunglife AI Inc6.82 MDNA Life SCIENCES, Inc.6.83 MDx Health6.84 Menarini Silicon Biosystems6.85 Mesa Laboratories, Inc.6.86 Millipore S.

Ltd6.15亿Toone6.16 Bioarray Genetics 6.17 Biocartis6.18 Biocept，Inc.6.19 Biodesix Inc.6.20 BioFluidica6.21 BioGenex6.22 BioIVT6.23 Biolidics Ltd6.24 bioMerieux Diagnostics 6.25 Bioneer Corporation 6.26 Bio-Rad Laboratories，Inc6.27 Bio-Reference Laboratories 6.28 Bio-Techne6.29 Bioview6.30 Bolidics6.31 Boreal Genomics6.32 Bristol-Myers Squibb6.33 Burning Rock6.34 Cardiff Oncology6.35 Caris Molecular诊断6.36 Castle Biosciences，Inc.6.37 Celemics6.38 CellCarta6.39 CellMax Life6.40造父变星（Danaher）6.41查尔斯河实验室6.42 Circulogene6.43 Cizzle Biotech6.44临床基因组学6.45 Cytolumina Technologies Corp.6.46 Datar癌症遗传学有限公司6.47 Diagnologix LLC6.48 Diasorin S.p.A.6.49 Dxcover6.50 Enzo Biochem6.51 Epic SCIENCES 6.52 Epigenomics AG6.53 Eurofins Scientific 6.54 Exact SCIENCES 6.55 Fabric Genomics 6.56 Fluxion Biosciences 6.57 Freenome6.58 Fujilm Wako Diagnostics 6.59 Fulgent Genetics6.60 Fyr Diagnostics 6.61 GeneFirst Ltd.6.62 Genetron Holdings6.63 GenomOncology6.64 GILUPI Nanomedizin6.65 Guardant Health 6.66 HansaBiomed6.67 HeiScreen6.68 Helomics6.69 HTG Molecular Diagnostics 6.70 iCellate6.71 ICON PLC6.72 Illumina6.73 Incell Dx6.74 Inivata6.75 INOVIQ6.76 Integrated Diagnostics 6.77 Invitae Corporation 6.78 Invivogen6.79 Invivoscribe6.80 Janssen Diagnostics 6.81 Lunglife AI Inc6.82 MDNA Life SCIENCES，Inc.6.83 MDx Health6.84 Menarini Silicon Biosystems 6.85 Mesa Laboratories，Inc.6.86 Millipore S。

For more information about this report visit https://www.researchandmarkets.com/r/le4son

有关此报告的更多信息，请访问https://www.researchandmarkets.com/r/le4son

About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

关于ResearchAndMarkets.com ResearchAndMarkets.com是全球领先的国际市场研究报告和市场数据来源。我们为您提供有关国际和地区市场、关键行业、顶尖公司、新产品和最新趋势的最新数据。

Media Contact:

媒体联系人：

Research and MarketsLaura Wood, Senior Managerpress@researchandmarkets.com For E.S.T Office Hours Call +1-917-300-0470For U.S./CAN Toll Free Call +1-800-526-8630For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716

研究与市场高级Slaura WoodManagerpress@researchandmarkets.com对于E.S.T办公时间，请拨打+1-917-300-0470（对于美国）/CAN免费电话+1-800-526-8630（对于GMT办公时间），请拨打+353-1-416-8900（对于美国）。S、 传真：646-607-1907传真（美国境外）：+353-1-481-1716

Logo - https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

徽标-https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets

来源研究和市场